The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Chemotherapy in Pharmaceuticals: Platinum-based cancer drug compositions. Buy the report here.

Smarter leaders trust GlobalData

Data Insights Chemotherapy in Pharmaceuticals: Platinum-based cancer drug compositions

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Bristol-Myers Squibb Co

Eisai Co Ltd

BioMarin Pharmaceutical Inc

Synlogic Inc

Nanobiotix SA

View all

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Platinum-based cancer drug compositions is a key innovation area in chemotherapy

Platinum-based drugs are chemotherapeutic agents used for the treatment of cancer. Several platinum-based drugs such as cisplatin, carboplatin and oxaliplatin are widely used in cancer therapy. These compounds cause their therapeutic effect by inhibiting DNA synthesis.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 320+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of platinum-based cancer drug compositions.

Key players in platinum-based cancer drug compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to platinum-based cancer drug compositions

Bristol-Myers Squibb is one of the leading patent filers in platinum-based drugs. The company has filed several patents involving platinum compounds and developed drugs such as cisplatin and carboplatin..

In terms of application diversity, Synlogic is the top company, followed by Traslational Cancer Drugs Pharma and
Calgent Biotechnology. By means of geographic reach, Nanobiotix holds the top position. BioMarin Pharmaceutical and Eisai are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.